Low alpha-fetoprotein hepatocellular carcinoma

Brian I. Carr, Petr Pancoska, Robert A. Branch

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background and Aim: A large proportion of hepatocellular carcinoma (HCC) patients do not secrete elevated levels of the tumor marker alpha-fetoprotein (AFP). There is little published guide to prognostic features of this patient subset. Methods: We interrogated a large HCC database in which all patients had been followed until death, to examine which features might be prognostically useful. Results: We found 413 biopsy-proven unresectable HCC patients with low serum AFP values. Serum gamma glutamyl transpeptidase (GGTP) levels were one of the most significant factors for survival. This dichotomization into low and high GGTP levels separated the patients into distinctive survival ranges. Patients with GGTP levels <110 U/100 mL and small tumors had longest survival > 795 days. Patients with GGTP ≥ 110 U/mL and large tumors with the presence of portal vein thrombosis had the shortest survival range of 300-560 days. Conclusions: Serum levels of the onco-fetal protein GGTP represent a useful prognostic parameter in HCC patients with low AFP levels.

Original languageEnglish
Pages (from-to)1543-1549
Number of pages7
JournalJournal of Gastroenterology and Hepatology
Volume25
Issue number9
DOIs
Publication statusPublished - 2010

Fingerprint

alpha-Fetoproteins
Hepatocellular Carcinoma
gamma-Glutamyltransferase
Survival
Serum
Fetal Proteins
Tumor Biomarkers
Portal Vein
Thrombosis
Databases
Biopsy

Keywords

  • gamma glutamyl transpeptidase
  • hepatocellular carcinoma
  • low alpha-fetoprotein
  • survival
  • tumor size

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Low alpha-fetoprotein hepatocellular carcinoma. / Carr, Brian I.; Pancoska, Petr; Branch, Robert A.

In: Journal of Gastroenterology and Hepatology, Vol. 25, No. 9, 2010, p. 1543-1549.

Research output: Contribution to journalArticle

Carr, Brian I. ; Pancoska, Petr ; Branch, Robert A. / Low alpha-fetoprotein hepatocellular carcinoma. In: Journal of Gastroenterology and Hepatology. 2010 ; Vol. 25, No. 9. pp. 1543-1549.
@article{c25a5a6431024d4cba35343cd3d6038d,
title = "Low alpha-fetoprotein hepatocellular carcinoma",
abstract = "Background and Aim: A large proportion of hepatocellular carcinoma (HCC) patients do not secrete elevated levels of the tumor marker alpha-fetoprotein (AFP). There is little published guide to prognostic features of this patient subset. Methods: We interrogated a large HCC database in which all patients had been followed until death, to examine which features might be prognostically useful. Results: We found 413 biopsy-proven unresectable HCC patients with low serum AFP values. Serum gamma glutamyl transpeptidase (GGTP) levels were one of the most significant factors for survival. This dichotomization into low and high GGTP levels separated the patients into distinctive survival ranges. Patients with GGTP levels <110 U/100 mL and small tumors had longest survival > 795 days. Patients with GGTP ≥ 110 U/mL and large tumors with the presence of portal vein thrombosis had the shortest survival range of 300-560 days. Conclusions: Serum levels of the onco-fetal protein GGTP represent a useful prognostic parameter in HCC patients with low AFP levels.",
keywords = "gamma glutamyl transpeptidase, hepatocellular carcinoma, low alpha-fetoprotein, survival, tumor size",
author = "Carr, {Brian I.} and Petr Pancoska and Branch, {Robert A.}",
year = "2010",
doi = "10.1111/j.1440-1746.2010.06303.x",
language = "English",
volume = "25",
pages = "1543--1549",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Low alpha-fetoprotein hepatocellular carcinoma

AU - Carr, Brian I.

AU - Pancoska, Petr

AU - Branch, Robert A.

PY - 2010

Y1 - 2010

N2 - Background and Aim: A large proportion of hepatocellular carcinoma (HCC) patients do not secrete elevated levels of the tumor marker alpha-fetoprotein (AFP). There is little published guide to prognostic features of this patient subset. Methods: We interrogated a large HCC database in which all patients had been followed until death, to examine which features might be prognostically useful. Results: We found 413 biopsy-proven unresectable HCC patients with low serum AFP values. Serum gamma glutamyl transpeptidase (GGTP) levels were one of the most significant factors for survival. This dichotomization into low and high GGTP levels separated the patients into distinctive survival ranges. Patients with GGTP levels <110 U/100 mL and small tumors had longest survival > 795 days. Patients with GGTP ≥ 110 U/mL and large tumors with the presence of portal vein thrombosis had the shortest survival range of 300-560 days. Conclusions: Serum levels of the onco-fetal protein GGTP represent a useful prognostic parameter in HCC patients with low AFP levels.

AB - Background and Aim: A large proportion of hepatocellular carcinoma (HCC) patients do not secrete elevated levels of the tumor marker alpha-fetoprotein (AFP). There is little published guide to prognostic features of this patient subset. Methods: We interrogated a large HCC database in which all patients had been followed until death, to examine which features might be prognostically useful. Results: We found 413 biopsy-proven unresectable HCC patients with low serum AFP values. Serum gamma glutamyl transpeptidase (GGTP) levels were one of the most significant factors for survival. This dichotomization into low and high GGTP levels separated the patients into distinctive survival ranges. Patients with GGTP levels <110 U/100 mL and small tumors had longest survival > 795 days. Patients with GGTP ≥ 110 U/mL and large tumors with the presence of portal vein thrombosis had the shortest survival range of 300-560 days. Conclusions: Serum levels of the onco-fetal protein GGTP represent a useful prognostic parameter in HCC patients with low AFP levels.

KW - gamma glutamyl transpeptidase

KW - hepatocellular carcinoma

KW - low alpha-fetoprotein

KW - survival

KW - tumor size

UR - http://www.scopus.com/inward/record.url?scp=77956038667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956038667&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1746.2010.06303.x

DO - 10.1111/j.1440-1746.2010.06303.x

M3 - Article

VL - 25

SP - 1543

EP - 1549

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

IS - 9

ER -